EDITORIAL

Year : 2013  |  Volume : 3  |  Issue : 1  |  Page : 1-2

Bedaquiline: First FDA-approved tuberculosis drug in 40 years

Rajiv Mahajan
Department of Pharmacology, Adesh Institute of Medical Sciences and Research, Bathinda, Punjab, India

Correspondence Address:
Rajiv Mahajan
Department of Pharmacology, Adesh Institute of Medical Sciences and Research, Bathinda - 151 101, Punjab
India

Source of Support: None, Conflict of Interest: None

Check

DOI: 10.4103/2229-516X.112228

References

1.	Walker J, Tadena N. J and J tuberculosis drug gets fast-track clearance. The Wall Street Journal, 2013 Jan 02. Available from: http://online.wsj.com/article/SB10001424127887323320404578213421059138236.html [Last cited on 2013 Mar 17].
2.	Matteelli A, Carvalho AC, Dooley KE, Kritski A. TMC207: The first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol 2010;5:849-58.
3.	Thomas K. FDA approves drug for resistant tuberculosis. Available from: http://www.nytimes.com/2013/01/01/business/fda-approves-new-tuberculosis-drug.html?_r=2 [Last cited on 2013 Mar 18].
4.	US Food and Drug Administration. FDA news release. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm [Last cited on 2013 Mar 18].

This article has been cited by 1 The structure-based virtual screening of non-benzofuran inhibitors against M. tuberculosis Pks13-TE for anti-tuberculosis phenotypic discovery Guode Zhao,Xirong Tian,Jian Wang,Maosheng Cheng,Tianyu Zhang,Zihou Wang New Journal of Chemistry. 2021; [Pubmed] | [DOI] 2 The Prospect of Repurposing Immunomodulatory Drugs for Adjunctive Chemotherapy against Tuberculosis: A Critical Review Chiyun Lee,Sanjib Bhakta Antibiotics. 2021; 10(1): 91 [Pubmed] | [DOI] 3 Tuberculosis: current scenario, drug targets, and future prospects Priyanka Bose,Amit K. Harit,Ratnesh Das,Samaresh Sau,Arun K. Iyer,Sushil K. Kashaw Medicinal Chemistry Research. 2021; [Pubmed] | [DOI] 4 TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus Jickky Palmae Sarathy,Uday S. Ganapathy,Matthew D. Zimmerman,Véronique Dartois,Martin Gengenbacher,Thomas Dick Antimicrobial Agents and Chemotherapy. 2020; 64(4) [Pubmed] | [DOI] 5 Microbial Resistance Movements: An Overview of Global Public Health Threats Posed by Antimicrobial Resistance, and How Best to Counter Sameer Dhingra,Nor Azlina A. Rahman,Ed Peile,Motiur Rahman,Massimo Sartelli,Mohamed Azmi Hassali,Tariqul Islam,Salequl Islam,Mainul Haque Frontiers in Public Health. 2020; 8 [Pubmed] | [DOI] 6 What are the origins of growing microbial resistance? Both Lamarck and Darwin were right Juan Alberto Guevara Salazar,Jessica Rubí Morán Díaz,Enrique Ramírez Segura,José Guadalupe Trujillo Ferrara Expert Review of Anti-infective Therapy. 2020; [Pubmed] | [DOI] 7 In Silico Strategies in Tuberculosis Drug Discovery Stephani Joy Y. Macalino,Junie B. Billones,Voltaire G. Organo,Maria Constancia O. Carrillo Molecules. 2020; 25(3): 665 [Pubmed] | [DOI] 8 Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China Abela Mpobela Agnarson,Xiao Chun Wang,Ravi Potluri,Hitesh Bhandari,Amit Dhir,Chrispin Kambili,Laurent Metz BMC Infectious Diseases. 2020; 20(1) [Pubmed] | [DOI] 9 Bedaquiline inhibits the yeast and human mitochondrial ATP synthases Min Luo,Wenchang Zhou,Hiral Patel,Anurag P. Srivastava,Jindrich Symersky,Michal M. Bonar,José D. Faraldo-Gómez,Maofu Liao,David M. Mueller Communications Biology. 2020; 3(1) [Pubmed] | [DOI] 10 Pretomanid: A novel therapeutic paradigm for treatment of drug resistant tuberculosis Uzma Parveen,Safura Sultana,Salva Fatima Heba,Rehab Rafi,Aisha Begum,Nausheen Fatima Indian Journal of Tuberculosis. 2020; [Pubmed] | [DOI] 11 Inhibition of the ATP synthase sensitizes Staphylococcus aureus towards human antimicrobial peptides Liping Liu,Christian Beck,Katrine Nøhr-Meldgaard,Andreas Peschel,Dorothee Kretschmer,Hanne Ingmer,Martin Vestergaard Scientific Reports. 2020; 10(1) [Pubmed] | [DOI] 12 One Step Forward: Successful End-of-Treatment Outcomes of Patients With Drug-Resistant Tuberculosis Who Received Concomitant Bedaquiline and Delamanid in Mumbai, India Mrinalini Das,Alpa Dalal,Chinmay Laxmeshwar,Shilpa Ravi,Fatima Mamnoon,Augusto C Meneguim,Roma Paryani,Taanya Mathur,Pramila Singh,Homa Mansoor,Stobdan Kalon,Farah Naz Hossain,Nathalie Lachenal,Sylvine Coutisson,Gabriella Ferlazzo,Petros Isaakidis Clinical Infectious Diseases. 2020; [Pubmed] | [DOI] 13 Design, Synthesis and Biological Evaluation of Anti-tuberculosis Agents based on Bedaquiline Structure Chengjun Wu,Jinghan Luo,Mengtong Wu,Fanzhen Meng,Zhiqiang Cai,Yu Chen,Tiemin Sun Medicinal Chemistry. 2020; 16(5): 703 [Pubmed] | [DOI] 14 The Biotin Biosynthetic Pathway in Mycobacterium tuberculosis is a Validated Target for the Development of Antibacterial Agents Matthew R. Bockman,Neeraj Mishra,Courtney C. Aldrich Current Medicinal Chemistry. 2020; 27(25): 4194 [Pubmed] | [DOI] 15 Essential Medicinal Chemistry of Essential Medicines Marta Serafini,Sarah Cargnin,Alberto Massarotti,Tracey Pirali,Armando A. Genazzani Journal of Medicinal Chemistry. 2020; [Pubmed] | [DOI] 16 Synthesis and Structure-Activity Relationship Studies of C2-Modified Analogs of the Antimycobacterial Natural Product Pyridomycin Maryline Kienle,Patrick Eisenring,Barbara Stoessel,Oliver Horlacher,Samuel Hasler,Gwénaëlle van Colen,Ruben C. Hartkoorn,Anthony Vocat,Stewart Cole,Karl-Heinz Altmann Journal of Medicinal Chemistry. 2020; [Pubmed] | [DOI] 17 Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds Garrett C. Moraski,Nathalie Deboosère,Kate L. Marshall,Heath A. Weaver,Alexandre Vandeputte,Courtney Hastings,Lisa Woolhiser,Anne J. Lenaerts,Priscille Brodin,Marvin J. Miller,Olivier Neyrolles PLOS ONE. 2020; 15(1): e0227224 [Pubmed] | [DOI] 18 Dual inhibition of the terminal oxidases eradicates antibiotic-tolerant Mycobacterium tuberculosis Bei Shi Lee,Kiel Hards,Curtis A Engelhart,Erik J Hasenoehrl,Nitin P Kalia,Jared S Mackenzie,Ekaterina Sviriaeva,Shi Min Sherilyn Chong,Malathy Sony S Manimekalai,Vanessa H Koh,John Chan,Jiayong Xu,Sylvie Alonso,Marvin J Miller,Adrie J C Steyn,Gerhard Grüber,Dirk Schnappinger,Michael Berney,Gregory M Cook,Garrett C Moraski,Kevin Pethe EMBO Molecular Medicine. 2020; [Pubmed] | [DOI] 19 Successful bedaquiline-containing antimycobacterial treatment in post-traumatic skin and soft-tissue infection by Mycobacterium fortuitum complex: a case report Johanna Erber,Simon Weidlich,Tristan Tschaikowsky,Kathrin Rothe,Roland M. Schmid,Jochen Schneider,Christoph D. Spinner BMC Infectious Diseases. 2020; 20(1) [Pubmed] | [DOI] 20 Effect of Natural Phenolics on Pharmacokinetic Modulation of Bedaquiline in Rat to Assess the Likelihood of Potential Food–Drug Interaction Pankul Kotwal,Ashish Dogra,Ankita Sharma,Shipra Bhatt,Abhishek Gour,Sumit Sharma,Priya Wazir,Parvinder Pal Singh,Ajay Kumar,Utpal Nandi Journal of Agricultural and Food Chemistry. 2020; [Pubmed] | [DOI] 21 Current advances in the clinical development of anti-tubercular agents Samanvai Reddy Tetali,Eswar Kunapaeddi,Raghu Prasad Mailavaram,Vinayak Singh,Pobitra Borah,Pran Kishore Deb,Katharigatta N. Venugopala,Wafa Hourani,Rakesh Kumar Tekade Tuberculosis. 2020; 125: 101989 [Pubmed] | [DOI] 22 Emergence of nontuberculous mycobacteria infections during bedaquiline-containing regimens in multidrug-resistant tuberculosis patients Jingtao Gao,Yi Pei,Xiaofeng Yan,Guomin Shi,Tongxin Li,Mengqiu Gao,Yuhong Liu,Yufeng Wang,Wei Shu,Li Liang,Yu Pang International Journal of Infectious Diseases. 2020; [Pubmed] | [DOI] 23 The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa Abela Mpobela Agnarson,Abeda Williams,Chrispin Kambili,Gunnar Mattson,Laurent Metz Expert Review of Anti-infective Therapy. 2020; : 1 [Pubmed] | [DOI] 24 Repurposed drug candidates for antituberculosis therapy Qi An,Chungen Li,Yao Chen,Yong Deng,Tao Yang,Youfu Luo European Journal of Medicinal Chemistry. 2020; : 112175 [Pubmed] | [DOI] 25 Functionalization at C2, C3, and C4 of quinolines: Discovery of water-soluble betaine dyes of C3 quinolinium derivatives with solvatochromic and pH-sensitive properties Sasithorn Sangher,Chatchai Kesornpun,Thammarat Aree,Chulabhorn Mahidol,Somsak Ruchirawat,Prasat Kittakoop Dyes and Pigments. 2020; 178: 108341 [Pubmed] | [DOI] 26 Cell wall peptidoglycan in Mycobacterium tuberculosis: An Achilles’ heel for the TB-causing pathogen Arundhati Maitra,Tulika Munshi,Jess Healy,Liam T Martin,Waldemar Vollmer,Nicholas H Keep,Sanjib Bhakta FEMS Microbiology Reviews. 2019; [Pubmed] | [DOI] 27 Synthesis and Study of New Quinolineaminoethanols as Anti-Bacterial Drugs J.W.C. Laumaillé,J.W.C. Dassonville-Klimpt,J.W.C. Peltier,J.W.C. Mullié,J.W.C. Andréjak,J.W.C. Da-Nascimento,J.W.C. Castelain,J.W.C. Sonnet Pharmaceuticals. 2019; 12(2): 91 [Pubmed] | [DOI] 28 Azaaurones as Potent Antimycobacterial Agents Active against MDR- and XDR-TB André Campaniço,Marta P. Carrasco,Mathew Njoroge,Ronnett Seldon,Kelly Chibale,João Perdigão,Isabel Portugal,Digby F. Warner,Rui Moreira,Francisca Lopes ChemMedChem. 2019; [Pubmed] | [DOI] 29 Plasticity of the Mycobacterium tuberculosis respiratory chain and its impact on tuberculosis drug development Tiago Beites,Kathryn O’Brien,Divya Tiwari,Curtis A. Engelhart,Shaun Walters,Jenna Andrews,Hee-Jeong Yang,Michelle L. Sutphen,Danielle M. Weiner,Emmanuel K. Dayao,Matthew Zimmerman,Brendan Prideaux,Prashant V. Desai,Thierry Masquelin,Laura E. Via,Véronique Dartois,Helena I. Boshoff,Clifton E. Barry,Sabine Ehrt,Dirk Schnappinger Nature Communications. 2019; 10(1) [Pubmed] | [DOI] 30 Antituberculosis Drug Interactions with Membranes: A Biophysical Approach Applied to Bedaquiline Marina Pinheiro,Heinz Amenitsch,Salette Reis Membranes. 2019; 9(11): 141 [Pubmed] | [DOI] 31 Synthesis, bioevaluation and molecular docking study of new piperazine and amide linked dimeric 1,2,3-triazoles Tejshri R. Deshmukh,Smita P. Khare,Vagolu S. Krishna,Dharmarajan Sriram,Jaiprakash N. Sangshetti,Vijay M. Khedkar,Bapurao B. Shingate Synthetic Communications. 2019; : 1 [Pubmed] | [DOI] 32 TBAJ-876 Displays Bedaquiline-Like Mycobactericidal Potency without Retaining the Parental Drug’s Uncoupler Activity Jickky Palmae Sarathy,Priya Ragunathan,Christopher B. Cooper,Anna M. Upton,Gerhard Grüber,Thomas Dick Antimicrobial Agents and Chemotherapy. 2019; 64(2) [Pubmed] | [DOI] 33 Antitubercular metabolites from the marine-derived fungus strain Aspergillus fumigatus MF029 Zhijun Song,Yu Liu,Jieyu Gao,Jiansen Hu,Hongtao He,Shengwang Dai,Luoqiang Wang,Huanqin Dai,Lixin Zhang,Fuhang Song Natural Product Research. 2019; : 1 [Pubmed] | [DOI] 34 Pyridine and nitro-phenyl linked 1,3,4-thiadiazoles as MDR-TB inhibitors Harun Patel,Harsha Jadhav,Iqrar Ansari,Rahul Pawara,Sanjay Surana European Journal of Medicinal Chemistry. 2019; 167: 1 [Pubmed] | [DOI] 35 Assessment of preclinical drug interactions of bedaquiline by a highly sensitive LC-ESI-MS/MS based bioanalytical method Pankul Kotwal,Asmita Magotra,Ashish Dogra,Sumit Sharma,Abhishek Gour,Shipra Bhatt,Priya Wazir,Parvinder Pal Singh,Gurdarshan Singh,Utpal Nandi Journal of Chromatography B. 2019; 1112: 48 [Pubmed] | [DOI] 36 Selective drug deposition in lungs through pulmonary drug delivery system for effective management of drug-resistant TB Kaksha Sankhe,Tabassum Khan,Chintan Bhavsar,Munira Momin,Abdelwahab Omri Expert Opinion on Drug Delivery. 2019; : 1 [Pubmed] | [DOI] 37 Structural simplification: an efficient strategy in lead optimization Shengzheng Wang,Guoqiang Dong,Chunquan Sheng Acta Pharmaceutica Sinica B. 2019; [Pubmed] | [DOI] 38 Identification of novel scaffolds targeting Mycobacterium tuberculosis Michael Dal Molin,Petra Selchow,Daniel Schäfle,Andreas Tschumi,Thomas Ryckmans,Stephan Laage-Witt,Peter Sander Journal of Molecular Medicine. 2019; [Pubmed] | [DOI] 39 Bedaquiline- versus injectable-containing drug-resistant tuberculosis regimens: a cost-effectiveness analysis Ana-Maria Ionescu,Abela Mpobela Agnarson,Chrispin Kambili,Laurent Metz,Jonathan Kfoury,Steven Wang,Abeda Williams,Vikram Singh,Adrian Thomas Expert Review of Pharmacoeconomics & Outcomes Research. 2018; : 1 [Pubmed] | [DOI] 40 Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis Diana Machado,Miriam Girardini,Miguel Viveiros,Marco Pieroni Frontiers in Microbiology. 2018; 9 [Pubmed] | [DOI] 41 Ultrasound Assisted Synthesis of 4-(Benzyloxy)-N-(3-chloro-2-(substitutedphenyl)-4-oxoazetidin-1-yl) Benzamide as Challenging Anti-Tubercular Scaffold Urja Nimbalkar,Julio Seijas,Rachna Borkute,Manoj Damale,Jaiprakash Sangshetti,Dhiman Sarkar,Anna Nikalje Molecules. 2018; 23(8): 1945 [Pubmed] | [DOI] 42 In vitro activity of collinin isolated from the leaves of Zanthoxylum schinifolium against multidrug- and extensively drug-resistant Mycobacterium tuberculosis Sukyung Kim,Hoonhee Seo,Hafij Al Mahmud,Md Imtiazul Islam,Byung-Eui Lee,Myoung-Lae Cho,Ho-Yeon Song Phytomedicine. 2018; [Pubmed] | [DOI] 43 Synthesis, Characterization, Molecular Docking Studies and Biological Evaluation of Some Conjugated Quinazoline-Sulfonamide Scaffold A. Sunil Kumar,Jyothi Kudva,B. R. Bharath,Vaishali M Rai,S. Madan Kumar,Vasantha Kumar,Shyama Prasad Sajankila ChemistrySelect. 2018; 3(48): 13586 [Pubmed] | [DOI] 44 Identification and characterization of aspartyl-tRNA synthetase inhibitors against Mycobacterium tuberculosis by an integrated whole-cell target-based approach Ramón Soto,Esther Perez-Herran,Beatriz Rodriguez,Bogdan M. Duma,Monica Cacho-Izquierdo,Alfonso Mendoza-Losana,Joel Lelievre,David Barros Aguirre,Lluis Ballell,Liam R. Cox,Luke J. Alderwick,Gurdyal S. Besra Scientific Reports. 2018; 8(1) [Pubmed] | [DOI] 45 Slow-Binding Inhibition of Mycobacterium tuberculosis Shikimate Kinase by Manzamine Alkaloids Johayra Simithy,Ngolui Rene Fuanta,Mansour Alturki,Judith V. Hobrath,Amir E. Wahba,Ivett Pina,Jnanendra Rath,Mark T. Hamann,Jack DeRuiter,Douglas C. Goodwin,Angela I. Calderón Biochemistry. 2018; 57(32): 4923 [Pubmed] | [DOI] 46 In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium abscessus Complex Barbara A. Brown-Elliott,Richard J. Wallace Antimicrobial Agents and Chemotherapy. 2018; 63(2): e01919-18 [Pubmed] | [DOI] 47 Design, Synthesis, and in vitro antitubercular activity of 1,2,3-triazolyl-dihydroquinoline derivatives Saleha Banu,Rajitha Bollu,Lingaiah Nagarapu,Jagadeesh Babu Nanubolu,Perumal Yogeswari,Dharmarajan Sriram,Shravan Kumar Gunda,Divyasphoorthi Vardhan Chemical Biology & Drug Design. 2018; [Pubmed] | [DOI] 48 Mycobacterial protein tyrosine kinase, PtkA phosphorylates PtpA at tyrosine residues and the mechanism is stalled by the novel series of inhibitors Swati Jaiswal,Aditi Chatterjee,Sapna Pandey,Kiran Lata,Ranjith Kumar Gadi,Rajesh Manda,Sanjay Kumar,Maddi Sridhar Reddy,Ravishankar Ramachandran,Kishore K. Srivastava Journal of Drug Targeting. 2018; : 1 [Pubmed] | [DOI] 49 Rational design of isonicotinic acid hydrazide derivatives with antitubercular activity: Machine learning, molecular docking, synthesis and biological testing Vasyl Kovalishyn,Julie Grouleff,Ivan Semenyuta,Vitaliy O. Sinenko,Sergiy R. Slivchuk,Diana Hodyna,Volodymyr Brovarets,Volodymyr Blagodatny,Gennady Poda,Igor V. Tetko,Larysa Metelytsia Chemical Biology & Drug Design. 2018; [Pubmed] | [DOI] 50 Tomatidine Is a Lead Antibiotic Molecule That Targets Staphylococcus aureus ATP Synthase Subunit C Maxime Lamontagne Boulet,Charles Isabelle,Isabelle Guay,Eric Brouillette,Jean-Philippe Langlois,Pierre-Étienne Jacques,Sébastien Rodrigue,Ryszard Brzezinski,Pascale B. Beauregard,Kamal Bouarab,Kumaraswamy Boyapelly,Pierre-Luc Boudreault,Éric Marsault,François Malouin Antimicrobial Agents and Chemotherapy. 2018; 62(6): e02197-17 [Pubmed] | [DOI] 51 Synthesis and mechanistic investigation of iron(II) complexes of isoniazid and derivatives as a redox-mediated activation strategy for anti-tuberculosis therapy Julie Laborde,Céline Deraeve,Francisca Gilmara de Mesquita Vieira,Alix Sournia-Saquet,Lionel Rechignat,Anne Drumond Villela,Bruno Lopes Abbadi,Fernanda Souza Macchi,Kenia Pissinate,Cristiano V. Bizarro,Pablo Machado,Luiz Augusto Basso,Geneviève Pratviel,Luiz Gonzaga de França Lopes,Eduardo Henrique Silva Sousa,Vania Bernardes-Génisson Journal of Inorganic Biochemistry. 2018; 179: 71 [Pubmed] | [DOI] 52 Total Synthesis and Conformational Study of Callyaerin A: Anti-Tubercular Cyclic Peptide Bearing a Rare Rigidifying (Z )-2,3- Diaminoacrylamide Moiety Shengping Zhang,Luis M. De Leon Rodriguez,Ivanhoe K. H. Leung,Gregory M. Cook,Paul W. R. Harris,Margaret A. Brimble Angewandte Chemie International Edition. 2018; [Pubmed] | [DOI] 53 Total Synthesis and Conformational Study of Callyaerin A: Anti-Tubercular Cyclic Peptide Bearing a Rare Rigidifying (Z )-2,3- Diaminoacrylamide Moiety Shengping Zhang,Luis M. De Leon Rodriguez,Ivanhoe K. H. Leung,Gregory M. Cook,Paul W. R. Harris,Margaret A. Brimble Angewandte Chemie. 2018; [Pubmed] | [DOI] 54 Scientific rationale for traditional use of plants to treat tuberculosis in the eastern region of the OR Tambo district, South Africa B. Madikizela,L.J. McGaw Journal of Ethnopharmacology. 2018; 224: 250 [Pubmed] | [DOI] 55 Alkylated/aminated nitroimidazoles and nitroimidazole-7-chloroquinoline conjugates: Synthesis and anti-mycobacterial evaluation Vincent Shalini,Albertus Viljoen,Laurent Kremer,Vipan Kumar Bioorganic & Medicinal Chemistry Letters. 2018; [Pubmed] | [DOI] 56 Destination of aminoglycoside antibiotics in the ‘post-antibiotic era’ Yoshiaki Takahashi,Masayuki Igarashi The Journal of Antibiotics. 2017; [Pubmed] | [DOI] 57 Synergistic Response of Rifampicin with Hydroperoxides on Mycobacterium: A Mechanistic Study Yesha S. Patel,Sarika Mehra Frontiers in Microbiology. 2017; 8 [Pubmed] | [DOI] 58 High-Content Screening of Raw Actinomycete Extracts for the Identification of Antituberculosis Activities Jinyeong Heo,Jiyoun Nam,Jichan Jang,David Shum,Constantin Radu,Jinhua Cheng,Hanki Lee,Joo-Won Suh,Vincent Delorme SLAS Discovery. 2017; 22(2): 144 [Pubmed] | [DOI] 59 Preliminary SAR and biological evaluation of antitubercular triazolothiadiazine derivatives against drug-susceptible and drug-resistant Mtb strains Ziqiang Li,Xiaoguang Bai,Qi Deng,Guoning Zhang,Lei Zhou,Yishuang Liu,Juxian Wang,Yucheng Wang Bioorganic & Medicinal Chemistry. 2017; 25(1): 213 [Pubmed] | [DOI] 60 Genomic Insight into Mechanisms of Reversion of Antibiotic Resistance in Multidrug Resistant Mycobacterium tuberculosis Induced by a Nanomolecular Iodine-Containing Complex FS-1 Aleksandr I. Ilin,Murat E. Kulmanov,Ilya S. Korotetskiy,Rinat A. Islamov,Gulshara K. Akhmetova,Marina V. Lankina,Oleg N. Reva Frontiers in Cellular and Infection Microbiology. 2017; 7 [Pubmed] | [DOI] 61 Trends in the discovery of new drugs for Mycobacterium tuberculosis therapy with a glance at resistance Vahid Lohrasbi,Malihe Talebi,Abed Zahedi Bialvaei,Lanfranco Fattorini,Michel Drancourt,Mohsen Heidary,Davood Darban-Sarokhalil Tuberculosis. 2017; [Pubmed] | [DOI] 62 Synthesis, biological evaluation, and molecular docking studies of novel 3-aryl-5-(alkyl-thio)-1H -1,2,4-triazoles derivatives targeting Mycobacterium tuberculosis Navnath D. Rode,Amol D. Sonawane,Laxman Nawale,Vijay M. Khedkar,Ramesh A. Joshi,Anjali P. Likhite,Dhiman Sarkar,Rohini R. Joshi Chemical Biology & Drug Design. 2017; [Pubmed] | [DOI] 63 Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis Ji-Chan Jang,Yong-Gyun Jung,Jungil Choi,Hyunju Jung,Sungweon Ryoo Journal of Microbiology. 2017; [Pubmed] | [DOI] 64 A temporal proteome dynamics study reveals the molecular basis of induced phenotypic resistance in Mycobacterium smegmatis at sub-lethal rifampicin concentrations Alexander D. Giddey,Elise de Kock,Kehilwe C. Nakedi,Shaun Garnett,Andrew J. M. Nel,Nelson C. Soares,Jonathan M. Blackburn Scientific Reports. 2017; 7: 43858 [Pubmed] | [DOI] 65 Synthesis, molecular docking, antimycobacterial and antimicrobial evaluation of new pyrrolo[3,2- c ]pyridine Mannich bases Gilish Jose,Tholappanavara H. Suresha Kumara,Haliwana B.V. Sowmya,Dharmarajan Sriram,Tayur N. Guru Row,Amar A. Hosamani,Sunil S. More,Bhavya Janardhan,B.G. Harish,Sandeep Telkar,Yalegara Siddappa Ravikumar European Journal of Medicinal Chemistry. 2017; 131: 275 [Pubmed] | [DOI] 66 Tuberculosis: Still a Way to go ahead for a Lead- A Review Priyanka Bose,Amit K Harit,Kamal Krishna Halder Journal of Analytical & Pharmaceutical Research. 2017; 5(6) [Pubmed] | [DOI] 67 Constraints of Drug Resistance in Mycobacterium tuberculosis - Prospects for Pharmacological Reversion of Susceptibility to Antibiotics Aleksandr I. Ilin,Murat E. Kulmanov,Ilya S. Korotetskiy,Marina V. Lankina,Gulshara K. Akhmetova,Sergey V. Shvidko,Oleg N. Reva The Open Conference Proceedings Journal. 2017; 8(1): 33 [Pubmed] | [DOI] 68 Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery Elisa Azzali,Diana Machado,Amit Kaushik,Federica Vacondio,Sara Flisi,Clotilde Silvia Cabassi,Gyanu Lamichhane,Miguel Viveiros,Gabriele Costantino,Marco Pieroni Journal of Medicinal Chemistry. 2017; [Pubmed] | [DOI] 69 In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex Barbara A. Brown-Elliott,Julie V. Philley,David E. Griffith,Foram Thakkar,Richard J. Wallace Antimicrobial Agents and Chemotherapy. 2017; 61(2) [Pubmed] | [DOI] 70 Discovery of in vitro antitubercular agents through in silico ligand-based approaches Daniela De Vita,Fabiana Pandolfi,Roberto Cirilli,Luigi Scipione,Roberto Di Santo,Laura Friggeri,Mattia Mori,Diego Fiorucci,Giorgio Maccari,Robert Selwyne Arul Christopher,Claudio Zamperini,Valentina Pau,Alessandro De Logu,Silvano Tortorella,Maurizio Botta European Journal of Medicinal Chemistry. 2016; 121: 169 [Pubmed] | [DOI] 71 N-Benzyl-4-((heteroaryl)methyl)benzamides: A New Class of Direct NADH-Dependent 2-transEnoyl-Acyl Carrier Protein Reductase (InhA) Inhibitors with Antitubercular Activity Ana Guardia,Gulcin Gulten,Raquel Fernandez,Jesus Gómez,Feng Wang,Maire Convery,Delia Blanco,María Martínez,Esther Pérez-Herrán,Marta Alonso,Fátima Ortega,Joaquín Rullás,David Calvo,Lydia Mata,Robert Young,James C. Sacchettini,Alfonso Mendoza-Losana,Modesto Remuiñán,Lluís Ballell Pages,Julia Castro-Pichel ChemMedChem. 2016; : n/a [Pubmed] | [DOI] 72 Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials Riya Moodley,Thomas R. Godec European Respiratory Review. 2016; 25(139): 29 [Pubmed] | [DOI] 73 Scaffold morphing leading to evolution of 2,4-diaminoquinolines and aminopyrazolopyrimidines as inhibitors of the ATP synthesis pathway Subramanyam J. Tantry,Vikas Shinde,Gayathri Balakrishnan,Shankar D. Markad,Amit K. Gupta,Jyothi Bhat,Ashwini Narayan,Anandkumar Raichurkar,Lalit Kumar Jena,Sreevalli Sharma,Naveen Kumar,Robert Nanduri,Sowmya Bharath,Jitendar Reddy,Vijender Panduga,K. R. Prabhakar,Karthikeyan Kandaswamy,Parvinder Kaur,Neela Dinesh,Supreeth Guptha,Ramanatha Saralaya,Manoranjan Panda,Suresh Rudrapatna,Meenakshi Mallya,Harvey Rubin,Takahiro Yano,Khisi Mdluili,Christopher B. Cooper,V. Balasubramanian,Vasan K. Sambandamurthy,Vasanthi Ramachandran,Radha Shandil,Stefan Kavanagh,Shridhar Narayanan,Pravin Iyer,Kakoli Mukherjee,Vinayak P. Hosagrahara,Suresh Solapure,Shahul Hameed P,Sudha Ravishankar Med. Chem. Commun.. 2016; [Pubmed] | [DOI] 74 Crystal structure ofMycobacterium tuberculosisketol-acid reductoisomerase at 1.0 Å resolution - a potential target for anti-tuberculosis drug discovery You Lv,Ajit Kandale,Shun Jie Wun,Ross P. McGeary,Simon J. Williams,Bostjan Kobe,Volker Sieber,Mark A. Schembri,Gerhard Schenk,Luke W. Guddat FEBS Journal. 2016; 283(7): 1184 [Pubmed] | [DOI] 75 Viability, morphology, and proteome ofMycobacterium smegmatis MSMEG_0319knockout strain Shanshan Sha,Xiaoxia Shi,Liming Xu,Jiabin Wen,Yi Xin,Yufang Ma PROTEOMICS. 2016; 16(7): 1090 [Pubmed] | [DOI] 76 Design, synthesis and biological evaluation of novel quinoline-based carboxylic hydrazides as anti-tubercular agents Subhash Chander,Penta Ashok,Davie Cappoen,Paul Cos,Sankaranarayanan Murugesan Chemical Biology & Drug Design. 2016; [Pubmed] | [DOI] 77 Synthesis and bioactivity of novel triazole incorporated benzothiazinone derivatives as antitubercular and antioxidant agent Mubarak H. Shaikh,Dnyaneshwar D. Subhedar,Manisha Arkile,Vijay M. Khedkar,Nandadeep Jadhav,Dhiman Sarkar,Bapurao B. Shingate Bioorganic & Medicinal Chemistry Letters. 2016; 26(2): 561 [Pubmed] | [DOI] 78 Development of acridine derivatives as selective Mycobacterium tuberculosis DNA gyrase inhibitors Brahmam Medapi,Nikhila Meda,Pushkar Kulkarni,Perumal Yogeeswari,Dharmarajan Sriram Bioorganic & Medicinal Chemistry. 2016; 24(4): 877 [Pubmed] | [DOI] 79 Synthesis and antitubercular and antibacterial activity of some active fluorine containing quinoline–pyrazole hybrid derivatives Nagabhushana Nayak,Jurupula Ramprasad,Udayakumar Dalimba Journal of Fluorine Chemistry. 2016; 183: 59 [Pubmed] | [DOI] 80 The pregnane X receptor in tuberculosis therapeutics Amina I Shehu,Guangming Li,Wen Xie,Xiaochao Ma Expert Opinion on Drug Metabolism & Toxicology. 2016; 12(1): 21 [Pubmed] | [DOI] 81 Emerging drugs and alternative possibilities in the treatment of tuberculosis S. Hofman,M.M. Segers,S. Ghimire,M.S. Bolhuis,M.G.G. Sturkenboom,D. Van Soolingen,J.W.C. Alffenaar Expert Opinion on Emerging Drugs. 2016; : 1 [Pubmed] | [DOI] 82 Synthesis, oxidation potential and anti-mycobacterial activity of isoniazid and analogues: insights into the molecular isoniazid activation mechanism Julie Laborde,Céline Deraeve,Léa Lecoq,Alix Sournia-Saquet,Jean-Luc Stigliani,Beatrice S. Orena,Giorgia Mori,Geneviève Pratviel,Vania Bernardes-Génisson ChemistrySelect. 2016; 1(2): 172 [Pubmed] | [DOI] 83 Identification of a novel class of quinoline–oxadiazole hybrids as anti-tuberculosis agents Puneet P. Jain,Mariam S. Degani,Archana Raju,Aarti Anantram,Madhav Seervi,Sadhana Sathaye,Muktikanta Ray,M.G.R. Rajan Bioorganic & Medicinal Chemistry Letters. 2016; 26(2): 645 [Pubmed] | [DOI] 84 Complete Genome Sequence of Multidrug-Resistant Clinical IsolateMycobacterium tuberculosis187.0, Used To Study the Effect of Drug Susceptibility Reversion by the New Medicinal Drug FS-1 Aleksandr I. Ilin,Murat E. Kulmanov,Ilya S. Korotetskiy,Gulshara K. Akhmetova,Marina V. Lankina,Sergey V. Shvidko,Oleg N. Reva Genome Announcements. 2015; 3(6): e01272-15 [Pubmed] | [DOI] 85 Bedaquiline and delamanid in tuberculosis Susanna Esposito,Sonia Bianchini,Francesco Blasi Expert Opinion on Pharmacotherapy. 2015; 16(15): 2319 [Pubmed] | [DOI] 86 Structural insights of PA-824 derivatives: ligand-based 3D-QSAR study and design of novel PA824 derivatives as anti-tubercular agents Bharathkumar Inturi,Gurubasavaraj V. Pujar,Madhusudhan N. Purohit Journal of Receptors and Signal Transduction. 2015; 35(5): 468 [Pubmed] | [DOI] 87 Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design Marco Pieroni,Baojie Wan,Valentina Zuliani,Scott G. Franzblau,Gabriele Costantino,Mirko Rivara European Journal of Medicinal Chemistry. 2015; 100: 44 [Pubmed] | [DOI] 88 Testing Tuberculosis Drug Efficacy in a Zebrafish High-Throughput Translational Medicine Screen Anita Ordas,Robert-Jan Raterink,Fraser Cunningham,Hans J. Jansen,Malgorzata I. Wiweger,Susanne Jong-Raadsen,Sabine Bos,Robert H. Bates,David Barros,Annemarie H. Meijer,Rob J. Vreeken,Lluís Ballell-Pages,Ron P. Dirks,Thomas Hankemeier,Herman P. Spaink Antimicrobial Agents and Chemotherapy. 2015; 59(2): 753 [Pubmed] | [DOI] 89 Preliminary Results of Bedaquiline as Salvage Therapy for Patients With Nontuberculous Mycobacterial Lung Disease Julie V. Philley,Richard J. Wallace,Jeana L. Benwill,Varsha Taskar,Barbara A. Brown-Elliott,Foram Thakkar,Timothy R. Aksamit,David E. Griffith Chest. 2015; 148(2): 499 [Pubmed] | [DOI] 90 Current perspectives in drug discovery against tuberculosis from natural products Joseph Mwanzia Nguta,Regina Appiah-Opong,Alexander K. Nyarko,Dorothy Yeboah-Manu,Phyllis G.A. Addo International Journal of Mycobacteriology. 2015; 4(3): 165 [Pubmed] | [DOI] 91 Structure, Dynamics, and Interaction of Mycobacterium tuberculosis (Mtb) DprE1 and DprE2 Examined by Molecular Modeling, Simulation, and Electrostatic Studies Isha Bhutani,Saurabh Loharch,Pawan Gupta,Rethi Madathil,Raman Parkesh,Chandra Verma PLOS ONE. 2015; 10(3): e0119771 [Pubmed] | [DOI] 92 Benzothiazinone-piperazine derivatives as efficient Mycobacterium tuberculosis DNA gyrase inhibitors Manoj Chandran,Janupally Renuka,Jonnalagadda Padma Sridevi,Ganesh S. Pedgaonkar,Vanaparthi Asmitha,Perumal Yogeeswari,Dharmarajan Sriram International Journal of Mycobacteriology. 2015; [Pubmed] | [DOI] 93 Design, Synthesis, and Biological Evaluation of New 8-Trifluoromethylquinoline Containing Pyrazole-3-carboxamide Derivatives Nagabhushana Nayak,Jurupula Ramprasad,Udayakumar Dalimba Journal of Heterocyclic Chemistry. 2015; : n/a [Pubmed] | [DOI] 94 Anything to Stay Alive: The Challenges of a Campaign for an Experimental Drug Nathan Geffen Developing World Bioethics. 2015; : n/a [Pubmed] | [DOI] 95 Novel isoniazid–amidoether derivatives: synthesis, characterization and antimycobacterial activity evaluation Deepak Kumar,Garima Khare,Beena Beena,Saqib Kidwai,Anil K. Tyagi,Ramandeep Singh,Diwan S. Rawat Med. Chem. Commun.. 2015; 6(1): 131 [Pubmed] | [DOI] 96 Diagnosis and treatment of multidrug-resistant tuberculosis Young Ae Kang Journal of the Korean Medical Association. 2014; 57(1): 27 [Pubmed] | [DOI] 97 Trends in discovery of new drugs for tuberculosis therapy Giovanna Riccardi,Maria Rosalia Pasca The Journal of Antibiotics. 2014; [Pubmed] | [DOI] 98 Synthesis of novel 1,2,3-triazole derivatives of isoniazid and their in vitro and in vivo antimycobacterial activity evaluation Deepak Kumar,Deepak Beena,Garima Khare,Saqib Kidwai,Anil K. Tyagi,Ramandeep Singh,Diwan S. Rawat European Journal of Medicinal Chemistry. 2014; [Pubmed] | [DOI] 99 TB Summit 2014: Prevention, diagnosis, and treatment of tuberculosis—a meeting report of a Euroscicon conference Arundhati Maitra,Sanjib Bhakta Virulence. 2014; 5(5): 638 [Pubmed] | [DOI] 100 Scaffold-switching: An exploration of 5,6-fused bicyclic heteroaromatics systems to afford antituberculosis activity akin to the imidazo[1,2-a]pyridine-3-carboxylates Garrett C. Moraski,Allen G. Oliver,Lowell D. Markley,Sanghyun Cho,Scott G. Franzblau,Marvin J. Miller Bioorganic & Medicinal Chemistry Letters. 2014; [Pubmed] | [DOI] 101 Synthesis and evaluation of anti-tubercular activity of 6-(4-substitutedpiperazin-1-yl) phenanthridine analogues Hunsur Nagendra Nagesh,Narva Suresh,Kalaga Mahalakshmi Naidu,Boyineni Arun,Jonnalagadda Padma Sridevi,Dharmarajan Sriram,Perumal Yogeeswari,Kondapalli Venkata Gowri Chandra Sekhar European Journal of Medicinal Chemistry. 2014; [Pubmed] | [DOI] 102 Design, synthesis and antimycobacterial activity of various 3-(4-(substitutedsulfonyl)piperazin-1-yl)benzo[d]isoxazole derivatives Kalaga Mahalakshmi Naidu,Amaroju Suresh,Jayanty Subbalakshmi,Dharmarajan Sriram,Perumal Yogeeswari,Pallepogu Raghavaiah,Kondapalli Venkata Gowri Chandra Sekhar European Journal of Medicinal Chemistry. 2014; 87: 71 [Pubmed] | [DOI] 103 Controlling strategy of dormant Mycobacterium tuberculosis Gan Yiling,Guo Shuliang Chinese Medical Journal. 2014; 127(18): 3316 [Pubmed] | [DOI] 104 Whole-Cell Screening-Based Identification of Inhibitors against the Intraphagosomal Survival of Mycobacterium tuberculosis Garima Khare,Praveen Kumar,Anil K. Tyagi Antimicrobial Agents and Chemotherapy. 2013; 57(12): 6372 [Pubmed] | [DOI] 105 Design, synthesis and evaluation of 6-(4-((substituted-1H-1,2,3-triazol-4-yl)methyl)piperazin-1-yl)phenanthridine analogues as antimycobacterial agents Hunsur Nagendra Nagesh,Kalaga Mahalakshmi Naidu,Damarla Harika Rao,Jonnalagadda Padma Sridevi,Dharmarajan Sriram,Perumal Yogeeswari,Kondapalli Venkata Gowri Chandra Sekhar Bioorganic & Medicinal Chemistry Letters. 2013; [Pubmed] | [DOI]